Literature DB >> 9634263

Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

F H Messerli1, E Grossman, U Goldbourt.   

Abstract

OBJECTIVE: To assess antihypertensive efficacy of beta-blockers and their effects on cardiovascular morbidity and mortality and all-cause morbidity compared with diuretics in elderly patients with hypertension. DATA SOURCE: A MEDLINE search of English-language articles published between January 1966 and January 1998 using the terms hypertension (drug therapy) and elderly or aged or geriatric, and cerebrovascular or cardiovascular diseases, and morbidity or mortality. References from identified articles were also reviewed. DATA SELECTION: Randomized trials lasting at least 1 year, which used as first-line agents diuretics and/or beta-blockers, and reported morbidity and mortality outcomes in elderly patients with hypertension. DATA SYNTHESIS AND
RESULTS: Ten trials involving a total of 16164 elderly patients (> or =60 years) were included. Two thirds of the patients assigned to diuretics were well controlled on monotherapy, whereas less than a third of the patients assigned to beta-blockers were well controlled on monotherapy. Diuretic therapy was superior to beta-blockade with regard to all end points and was effective in preventing cerebrovascular events (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.51-0.72), fatal stroke (OR, 0.67; 95% CI, 0.49-0.90), coronary heart disease (OR, 0.74; 95% CI, 0.64-0.85), cardiovascular mortality (OR, 0.75; 95% CI, 0.64-0.87), and all-cause mortality (OR, 0.86; 95% CI, 0.77-0.96). In contrast, beta-blocker therapy only reduced the odds for cerebrovascular events (OR, 0.75; 95% CI, 0.57-0.98) but was ineffective in preventing coronary heart disease, cardiovascular mortality, and all-cause mortality (ORs, 1.01, 0.98, and 1.05, respectively).
CONCLUSIONS: In contrast to diuretics, which remain the standard first-line therapy, beta-blockers, until proven otherwise, should no longer be considered appropriate first-line therapy of uncomplicated hypertension in the elderly hypertensive patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634263     DOI: 10.1001/jama.279.23.1903

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  108 in total

Review 1.  Geriatric medicine.

Authors:  S E Straus
Journal:  BMJ       Date:  2001-01-13

2.  Management of hypertension. Ideal body weight is not realistic goal for lifestyle intervention.

Authors:  J Wilding; G Williams
Journal:  BMJ       Date:  2000-02-26

Review 3.  Recent advances in the management of hypertension in the elderly.

Authors:  F J Gennari; A S Gennari
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

4.  Progress in secondary prevention of stroke with PROGRESS. The perindopril protection against recurrent stroke study.

Authors:  Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

5.  Hypertension in diabetes mellitus: role of beta-blockers.

Authors:  F H Messerli; E Grossman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  What are the elements of good treatment for hypertension?

Authors:  C D Mulrow; M Pignone
Journal:  BMJ       Date:  2001-05-05

Review 7.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 8.  Old antihypertensive agents-diuretics and beta-blockers: do we know how and in whom they lower blood pressure?

Authors:  D A Sica
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

9.  Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.

Authors:  F H Messerli; E Grossman
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

10.  Current trials.

Authors:  F H Messerli
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.